European Union leaders ended a second day of negotiations late on Saturday without a concrete plan to pump hundreds of billions of euros into their economies ravaged by coronavirus and would resume on Sunday. Conway G. Gittens has the details.
European Commission Vice President Margaritis Schinas talks to the Global Conversation about the future of Europe's border-free travel Schengen zone and what European solidarity should look like once Europe comes out of the coronavirus crisis.View on euronews
Credit: euronews (in English) Duration: 08:13Published
The antiviral drug Remdesivir has proven to be effective in the treatment of COVID-19. According to UPI, the drug can lower the risk of death in COVID-19 patients by 62%. U.S. drugmaker Gilead Sciences reported the new data on Friday. Gilead said the results came from a comparative analysis among 312 patients in its Phase 3 clinical trial. There have been over 3.4 million confirmed cases of coronavirus in the U.S., with a death toll of 138,247 people.
U.S. stocks rose Friday as a positive analysis on Gilead Sciences Inc's antiviral drug to treat COVID-19 helped to soothe investor worries over a record rise in coronavirus cases in the United States. Fred Katayama reports.
Gilead Sciences said Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients. Fred Katayama reports.
Gilead is the pharmaceutical company behind a drug that’s been approved for COVID emergencies. The FDA officially announced the medicine could be used in treating COVID-19 patients. Gilead has now announced the drug will cost $3,120 per typical treatment course for insured individuals. Research has indicated the drug could cut the recovery time for hospitalized COVID-19 patients. It could shorten satsy by several days, reports Gizmodo.
Chancellor Rishi Sunak says the government is making “good progress” on Brexit deal negotiations with the European Union ahead of the December 31st deadline but adds that “there remain gaps on a couple of big issues”. Report by Jonesia. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
The opposition in Belarus rejected official election results handing President Alexander Lukashenko a landslide re-election victory on Monday, saying the poll was rigged and that talks needed to begin on a peaceful transfer of power. Emer McCarthy reports.
Shares of Moderna jumped before paring their gains Wednesday after analysts said a $1.5 billion coronavirus vaccine supply agreement with the U.S. government could lead to similar deals with other countries. Fred Katayama reports.
Apple shares have risen more than 50% this year, but O'Neil Global Advisors' Randy Watts says don't take profits ahead of their 5G rollout. He also tells Reuters' Fred Katayama that the U.S. dollar's recent drop makes emerging markets stocks and gold more attractive.
The Dow jumped 1%, the S&P 500 inched up and the Nasdaq closed lower Monday as investors extended a rotation into value stocks from heavyweight tech-related names while awaiting news on progress in a U.S. fiscal support bill. Fred Katayama reports.